Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice.
A diabetogenic alloxan regimen produced lesions in all stomachs of treated animals, either rats (200 mg x kg(-1) s.c.) or mice (400 mg x kg(-1) i.p.). In control animals, the lesions, when developed (i.e. 24 h following application), appear to be quite sustained, and consistently present also after 1 or 2 weeks. The application of the pentadecapeptide BPC 157 (10 microg or 10 ng x kg(-1) i.p. coadministered together with alloxan) would significantly attenuate these lesions' appearance. This beneficial effect seems to be present in either rats or mice and in either of the tested intervals. Importantly, the beneficial effect seems to be shared by both microgram and nanogram regimens.
Petek
M
M
Department of Pharmacology, Medical Faculty, University of Zagreb, Croatia.
Sikiric
P
P
Anic
T
T
Buljat
G
G
Separovic
J
J
Stancic-Rokotov
D
D
Seiwerth
S
S
Grabarevic
Z
Z
Rucman
R
R
Mikus
D
D
Zoricic
I
I
Prkacin
I
I
Sebecic
B
B
Ziger
T
T
Coric
V
V
Turkovic
B
B
Aralica
G
G
Rotkvic
I
I
Mise
S
S
Hahn
V
V
D000496:Alloxan; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010446:Peptide Fragments / Q000494:pharmacology*; D011506:Proteins / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013276:Stomach Ulcer / Q000139:chemically induced* / Q000473:pathology*
D000897:Anti-Ulcer Agents; D010446:Peptide Fragments; D011506:Proteins; D000496:Alloxan; C083833:BPC 157